Novartis

News

NICE approves Novartis' CAR-T therapy for diffuse large B-ce...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments.

News

Novartis spent $15bn on M&A last year, with more to come

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum.

News

Novartis makes quality of life case for Cosentyx with new da...

There is increasing recognition that skin clearance scores may not be enough to win over patients and doctors when it comes to the highly competitive market for psoriasis drugs, even though

News

Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech...

Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZe

News

NICE rejects Novartis’ migraine prevention drug Aimovig

Some migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are facing disappointment after NICE rejected it in draft guidance.

News

Novartis' sickle cell drug gets Breakthrough Therapy designa...

The FDA has granted Breakthrough Therapy designation to Novartis' crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with

NICE approves Novartis' CAR-T therapy for diffuse large B-ce...

Novartis spent $15bn on M&A last year, with more to come

Novartis makes quality of life case for Cosentyx with new da...

Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech...

NICE rejects Novartis’ migraine prevention drug Aimovig

Novartis' sickle cell drug gets Breakthrough Therapy designa...

Lilly strikes $8.8bn-plus alliance with China's Innovent

How to meet your physicians where they are online

Novartis

Editor's Picks